SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Gale Robert))
 

Search: (WFRF:(Gale Robert)) > Myeloablative vs re...

  • Chhabra, SaurabhMed Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA (author)

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • 2018-11-05
  • American Society of Hematology,2018
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-371540
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-371540URI
  • https://doi.org/10.1182/bloodadvances.2018024844DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:142588656URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease status at transplant was divided into the following categories: chronic phase 1, chronic phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and alternative donor transplants were excluded. The primary outcome was overall survival (OS) after allo-HCT. MAC (n = 1204) and RIC allo-HCT recipients (n = 191) from 2007 to 2014 were included. Patient, disease, and transplantation characteristics were similar, with a few exceptions. Multivariable analysis showed no significant difference in OS between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P = .001). The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with RIC than with MAC (HR, 0.77; P = .02). RIC provides similar survival and lower cGVHD compared with MAC and therefore may be a reasonable alternative to MAC for CML patients in the TKI era.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ahn, Kwang WooMed Coll Wisconsin, Inst Hlth & Soc, Dept Biostat, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA (author)
  • Hu, Zhen-HuanMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA (author)
  • Jain, SandeepMed Univ South Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA (author)
  • Assal, AmerColumbia Univ, Med Ctr, New York, NY USA (author)
  • Cerny, JanUMass Mem Med Ctr, Worcester, MA USA (author)
  • Copelan, Edward A.Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA (author)
  • Daly, AndrewTom Baker Canc Clin, Calgary, AB, Canada (author)
  • DeFilipp, ZachariahMassachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA 02114 USA (author)
  • Gadalla, Shahinaz M.NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA (author)
  • Gale, Robert PeterImperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England (author)
  • Ganguly, SiddharthaUniv Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA (author)
  • Hamilton, Betty K.Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA (author)
  • Hildebrandt, Gerhard CarlUniv Kentucky, Markey Canc Ctr, Lexington, KY USA (author)
  • Hsu, Jack W.Shands HealthCare, Dept Med, Div Hematol & Oncol, Gainesville, FL USA;Univ Florida, Gainesville, FL USA (author)
  • Inamoto, YoshihiroNatl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan (author)
  • Kanate, Abraham S.West Virginia Univ, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA (author)
  • Khoury, H. JeanEmory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA (author)
  • Lazarus, Hillard M.Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Seidman Canc Ctr, Cleveland, OH 44106 USA (author)
  • Litzow, Mark R.Mayo Clin Rochester, Div Hematol & Transplant Ctr, Rochester, MN USA (author)
  • Nathan, SunitaRush Univ, Med Ctr, Chicago, IL 60612 USA (author)
  • Olsson, RichardKarolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden(Swepub:uu)riols677 (author)
  • Pawarode, AttapholUniv Michigan, Dept Internal Med, Div Hematol Oncol, Med Sch,Blood & Marrow Transplantat Program, Ann Arbor, MI 48109 USA (author)
  • Ringden, OlleKarolinska Institutet (author)
  • Rowe, Jacob M.Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel (author)
  • Saad, AymanUniv Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA (author)
  • Savani, Bipin N.Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA (author)
  • Schouten, Harry C.Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands (author)
  • Seo, SachikoNatl Canc Res Ctr East, Dept Hematol & Oncol, Chiba, Japan (author)
  • Shah, Nirav N.Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA (author)
  • Solh, MelhemNorthside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA (author)
  • Stuart, Robert K.Med Univ South Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA (author)
  • Ustun, CelalettinUniv Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA (author)
  • Woolfrey, Ann E.Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA (author)
  • Yared, Jean A.Univ Maryland, Greenebaum Canc Ctr, Div Hematol Oncol, Blood & Marrow Transplantat Program,Dept Med, Baltimore, MD 21201 USA (author)
  • Alyea, Edwin P.Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA (author)
  • Kalaycio, Matt E.Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA (author)
  • Popat, UdayUniv Texas MD Anderson Canc Ctr, Houston, TX 77030 USA (author)
  • Sobecks, Ronald M.Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA (author)
  • Saber, WaelMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA (author)
  • Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USAMed Coll Wisconsin, Inst Hlth & Soc, Dept Biostat, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA (creator_code:org_t)

Related titles

  • In:Blood Advances: American Society of Hematology2:21, s. 2922-29362473-95292473-9537

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view